The AHA has published a scientific statement regarding the screening, diagnosis, and management of hypertriglyceridemia in pediatric patients.

The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia-abnormal ...

A Prescription Drug User Fee Act target date of June 30, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug ...

WASHINGTON and DALLAS, March 13, 2026 /PRNewswire/ -- The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen ...

Eliana Merle Barclays Bank PLC, Research Division. Great. Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Very happy to have Ionis here wi ...

In recent weeks, Ionis Pharmaceuticals announced that the FDA accepted a Priority Review for olezarsen in severe hypertriglyceridemia, released 2026 revenue guidance of US$800 million to US$825 ...

Ionis Pharmaceuticals received FDA Priority Review for its supplemental New Drug Application for olezarsen, targeting severe hypertriglyceridemia and reduction of acute pancreatitis risk. The company ...

Amarin’s latest analyst update keeps the price target steady at US$12.00, matching the prior US$12 figure and signaling that the core valuation anchor has not shifted. Analysts are now explaining how ...

CARLSBAD, Calif. - Ionis Pharmaceuticals (NASDAQ:IONS) announced today that the U.S. Food and Drug Administration has accepted for Priority Review its supplemental New Drug Application for olezarsen ...

USA: A cross-sectional study has found that women with multiple cardiometabolic risk factors have disproportionately higher odds of clinically significant liver fibrosis compared with men with similar ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial ...